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Abstract
Background: Spondylodysplastic EDS (spEDS) is a rare connective tissue disorder that groups the phenotypes
caused by biallelic B4GALT7, B3GALT6, and SLC39A13 mutations. In the 2017 EDS nosology, minimal criteria (general
and gene-specific) for a clinical suspicion of spEDS have been proposed, but molecular analysis is required to reach
a definite diagnosis. The majority of spEDS patients presented with short stature, skin hyperextensibility, facial
dysmorphisms, peculiar radiological findings, muscle hypotonia and joint laxity and/or its complications. To date
only 7 patients with β4GALT7-deficiency (spEDS-B4GALT7) have been described and their clinical data suggested
that, in addition to short stature and muscle hypotonia, radioulnar synostosis, hypermetropia, and delayed
cognitive development might be a hallmark of this specific type of spEDS. Additional 22 patients affected with
an overlapping phenotype, i.e., Larsen of Reunion Island syndrome, all carrying a homozygous B4GALT7 mutation,
are also recognized.
Results: Herein, we report on a 30-year-old Moroccan woman who fitted the minimal criteria to suspect spEDS,
but lacked radioulnar synostosis and intellectual disability and presented with neurosensorial hearing loss and limb
edema of lymphatic origin. Sanger sequencing of B4GALT7 was performed since the evaluation of the spEDS
gene-specific minor criteria suggested this specific subtype. Mutational screening revealed the homozygous c.
829G>T, p.Glu277* pathogenetic variant leading to aberrant splicing.
Conclusions: Our findings expand both the clinical and mutational spectrum of this ultrarare connective tissue
disorder. The comparison of the patient’s features with those of the other spEDS and Larsen of Reunion Island
syndrome patients reported up to now offers future perspectives for spEDS nosology and clinical research in
this field.
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Introduction
Spondylodysplastic Ehlers-Danlos syndrome (spEDS) is a
rare autosomal recessive connective tissue disorder with
an unknown frequency and prevalence. In the 2017 re-
vised EDS classification, spEDS groups the phenotypes
caused by biallelic B4GALT7, B3GALT6, and SLC39A13
mutations within the same clinical entity in consideration
of the reliable clinical overlap [1]. Two major criteria,
i.e., short stature and muscle hypotonia, plus character-
istic radiographic abnormalities and at least three other
minor criteria are minimal criteria suggestive for spEDS
[1, 2]. Confirmatory molecular testing is mandatory to
reach a final diagnosis. B4GALT7 and B3GALT6 encode
galactosyltransferase I (β4GALT7) and II (β3GALT6),
respectively, that are Golgi-resident enzymes involved
in synthesizing the glycosaminoglycan (GAG) linker re-
gion of proteoglycans [3]; SLC39A13 encodes the trans-
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membrane Zrt/irt like protein 13 (ZIP13) that regulates
the influx of zinc into the cytosol [4].
At present, 7 patients from 6 families with molecularly
confirmed spEDS due to β4Galt7-deficiency (spEDS-
B4GALT7) have been reported and a total of 7 missense
and 2 frameshift mutations are recognized [3, 5–8]. All or
the majority of reported patients with spEDS-B4GALT7
showed short stature, muscle hypotonia, radioulnar synos-
tosis, and mild to severe intellectual disability (ID), conse-
quently, these items were assumed to be the hallmark of
the disorder [1, 2, 7]. Other frequent features comprised
facial dysmorphism, hyperextensible skin, joint hypermo-
bility (JHM), single transverse palmar crease, severe
hypermetropia, limb bowing, and osteopenia, [2]. Further
22 patients, all with the same homozygous B4GALT7
p.(Arg270Cys) missense mutation and strict clinical over-
lap with spEDS-B4GALT7, have been characterized in the
ethnic group called white creoles living on Reunion Island
(Larsen of Reunion Island syndrome, LRS) [9].
Herein we describe an additional patient with a novel
homozygous B4GALT7 causative variant and compare
her clinical features with those of the other spEDS and
LRS patients reported so far, thus expanding the pheno-
type of the disorder and its allelic repertoire.
Patient report
The proposita, a 30-year-old Moroccan woman, was
born from healthy, apparently non-consanguineous par-
ents and had a healthy younger sister. Perinatal distress
was absent. At birth, measurements were within normal
range; neonatal hypotonia and slight delayed motor de-
velopment were noted. In infancy, progressive height
deficit not related to GH deficiency was present, and a
clinical diagnosis of unspecified EDS was given for skin
hyperextensibility and generalized JHM. At age 28, dual-
energy X-ray absorptiometry disclosed low bone mineral
density for sex and age (z-score < 2 SD); audiometric
test revealed mild neurosensorial hearing loss. Genetic
analyses were not performed.
On examination, disproportionate short stature (145 cm,
genetic target 160 cm, standard deviation from ethnic aver-
age stature – 2, arm span/height ratio 1.09, n.v. <1.05), soft,
doughy, hyperextensible skin, small atrophic scars on knees
and a single transverse palmar crease were observed
(Fig. 1A). gJHM according to the Beighton score (7/9), skel-
etal abnormalities (scoliosis, severe hallux valgus, pes pla-
nus, low-set thumb, clinodactyly of the 5th fingers),
generalized muscle hypotonia, facial dysmorphism (light
blue sclerae, wide forehead, flat face, sparse scalp hair, and
narrow mouth), and edema of the lower extremities were
also noticed (Fig.1A). Complication of gJHM were recur-
rent sprains, temporomandibular joint dislocation and
chronic pain at cervical spine, right shoulder, and ankles.
Doppler ultrasound of lower limbs established edema of
lymphatic origin; lymphography was not performed ac-
cording to the patient’s choice. The most frequent
causes of secondary lymphedema, i.e., cancer, infection,
and surgery, were not present. Ophthalmologic evalu-
ation was unremarkable for refractive errors including
hypermetropia. Forearms, left wrist, pelvis, lower limbs,
feet and spine X-ray disclosed dextroscoliosis, L5 hemi-
sacralitation, L4-L5 disc space narrowing, metatarso-
phalangeal subluxation, pes planus, and hallux valgus
(Fig. 1B). Heart ultrasound detected normal cardiac/
valve morphology and function. Cognitive development
and mentation were normal.
This phenotype was suggestive for spEDS, since the
patient fulfilled 2 major and 4 minor criteria according
to the 2017 EDS nosology (Table 1), and the evaluation
of the gene-specific minor criteria suggested B4GALT7
as causative gene (Table 2).
Therefore, after written informed consent was ob-
tained, B4GALT7 mutational screening was performed
by Sanger sequencing of all coding exons/intron
boundaries. This analysis disclosed in the patient the
homozygous c.829G>T (p.Glu277*) variant; both par-
ents and her sister were heterozygotes (Fig. 1C). All
these carriers did not show any sign of the disease in-
cluding short stature, muscle hypotonia, craniofacial
dysmorphism, as well as hearing loss and lymphedema.
The identified variant represents a very rare allele seen
only twice in 122,600 samples from the genome Aggre-
gation Database (gnomAD) with an allele frequency of
8.157e−6. Though patient's parents firmly denied consan-
guinity, the presence of some not-so-distant relatedness
should not be excluded; homozygosity mapping was not
performed, since they did not consent further investiga-
tions. Alternatively, the allele might be more common in
Morocco, but no population-specific data are available.
The transversion affects the first nucleotide of the last
exon and the splice site prediction tools of the Alamut
Visual version 2.9.0 software suggested that the variant
alters the canonical splice acceptor site. To verify the
possible splice effect of the variant, RT-PCR was carried
out by standard procedures on RNA extracted from pa-
tient’s whole blood. That demonstrated multiple splice
outcomes. In particular, agarose gel electrophoresis of
patient’s cDNA amplified with primers encompassing
exons 4–6 showed, in addition to low amounts of wild
type fragment (188 bp), the presence of an aberrant
band (713 bp). Sanger sequencing of this RT-PCR
showed in addition to mRNA resulting from the use of
the canonical site, the presence of 2 further splice prod-
ucts: i) an allele derived from the activation of a cryptic
splice acceptor site 3 bp downstream generating in-
frame deletion of the amino acid residue at position
277, and ii) mRNA with entire intron 5 retention caus-
ing the insertion of 10 amino acids followed by a stop
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codon (Fig. 1C). The mutation should therefore result
in different amounts of truncated (p.Glu277* and
p.Glu276_Glu277ins11*) and internally deleted poly-
peptides (p.Glu277del) leading to reduced galactosyl-
transferase activity. The resulting functional implication
on GAG synthesis was not studied, since fibroblasts were
not available.
Discussion
spEDS-B4GALT7 is an extremely rare and consequently
poorly characterized entity. In the past, nosologic con-
fusion characterized this disorder, since patients with
B4GALT7 mutations were alternatively labelled as EDS
progeroid type [5, 6], EDS with short stature and limb
anomalies [7], linkeropathy [3], and LRS [9]. The term
“progeroid” was originally used due to the phenotypic
resemblance including mild aged appearance, which
was observed among patients with β4Galt7-deficiency
of the first reports [5, 6] and those categorized as EDS
progeroid variant by Hernandez et al. [10–12]. Description
of further patients did not confirm the association of
β4Galt7-deficiency with early aging [7–9]. The umbrella
term linkeropathies refers to the overlapping phenotypes
caused by mutations in genes encoding for the enzymes
involved in the synthesis of the GAG linker region that
include, apart from B4GALT7 and B3GALT6, also
B3GAT3 and XYLT1/2 encoding glucuronyltransferase I
and xylosyltransferase I/II, respectively [13].
In the 2017 EDS nosology, the entity “EDS progeroid
type” is no longer listed and B4GALT7 and B3GALT6-
related linkeropathies were grouped as spEDS together
with patients harboring SLC39A13 mutations [1]. Pa-
tients with B3GAT3 and XYLT1/2 mutations were not
classified as spEDS even if numerous common features
are recognized, i.e., short stature, muscle hypotonia, cu-
taneous signs, gJHM, characteristic radiographic find-
ings (foot abnormalities, peculiar fingers, swedish key
appearance of femora, metaphyseal widening, radioul-
nar synostosis), and facial dysmorphism (prominent
forehead, blue sclerae, proptosis, small mouth, and de-
pressed nasal bridge) [13–15].
Minimal criteria to suspect spEDS have been proposed
based on the clinical findings of reported patients [2].
Concerning spEDS-B4GALT7 clinical data of 7 molecu-
larly characterized EDS patients were considered, whereas
the 22 LRS patients were not included. Consistent with
the proposed criteria, our patient further reinforces the
concept that short stature and muscle hypotonia really
seem the prominent features of spEDS-B4GALT7, since
they have been observed in all patients described so far.
Considering all the spEDS types, these two features were
(See figure on previous page.)
Fig. 1 Clinical and molecular findings of the patient. a Facial features, i.e., light blue sclerae, wide forehead, flat face, sparse scalp hair, narrow
mouth (i), skin hyperextensibility on the neck and dorsum of the hand (ii, iii), single palmar crease and laxity of the thumb (iv), laxity of the fifth
finger (v), small atrophic scar on knee (vi), low-set thumb and clinodactyly of the fifth finger (vii), disproportionate short stature, hypotonia and
edema of the lower limbs (viii, ix), pes planus and hallux valgus (x). b Absence of radioulnar synostosis (i-iii), osteopenia and absence of metaphyseal
flaring (iv), metatarsophalangeal subluxation and severe hallux valgus (v). c Sequence chromatograms showing the position of the homozygous
B4GALT7 c.829G>T variant (arrow) (seq. Ref.: NM_007255.2, NP_009186.1) (i). RT-PCR with a primer pair encompassing exons 4–6 performed on total
RNA from patient’s blood demonstrated that the c.829G>T transversion, which affects the first nucleotide of exon 6, impacts splicing (ii). In particular,
apart from the usage of the wild type acceptor (allele 1), an alternative acceptor 3 bp downstream (allele 2), and the presence of a splice product with
retention of intron 5 (allele 3) were disclosed (iii). These different alleles should lead to a truncated protein (p.Glu277*), in-frame deletion (p.Glu277del),
and insertion of 10 amino acids followed by a stop codon (p.Glu276_Glu277ins11*), respectively
Table 1 Major and minor criteria of spEDS according to the 2017 EDS nosology [1, 2] and comparison to LRS [9]
Present patient spEDS-B4GALT7 (%)a spEDS-B3GALT6 (%) spEDS-SLC39A13 (%) Total spEDS (%) LRS (%)
MAJOR CRITERIA
Short stature + 8/8 (100) 26/36 (72.2) 7/8 (87.5) 41/52 (78.8) 19/19 (100)
Muscle hypotonia + 8/8 (100) 16/36 (44.4) 6/8 (75.0) 30/52 (57.6) na
Bowing of limbs – 5/8 (62.5) 3/36 (8.3) na 8/44 (18.1) –
MINOR CRITERIA
Hyperextensible, soft, doughy, and
thin skin
+ 7/8 (87.5) 19/36 (52.7) 6/8 (75.0) 32/52 (61.5) 21/22 (95.4)
Pes planus/equinovarus/valgus + 6/8 (75.0) 21/36 (58.3) 6/8 (75.0) 33/52 (63.4) na
Delayed motor development + 7/8 (87.5) 7/36 (19.4) – 14/52 (26.9) na
Osteopenia + 5/8 (62.5) 12/36 (33.3) 3/8 (37.5) 20/52 (38.4) –
Delayed cognitive development – 5/8 (62.5) 11/36 (30.5) – 16/52 (30.7) 12/22 (54.5)
na not available
apresent patient included
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present in about 80 and 58%, respectively. Severe short
stature has been disclosed also in LRS patients, while data
concerning muscle hypotonia were not available (Table 1).
Bowing of limbs, the third major criterion of spEDS, was
reported only in about 18% of spEDS patients, whereas it
was found more frequently in spEDS-B4GALT7,
suggesting that this sign might be more specific of this
subtype of spEDS (Table 1, [2]). Other frequent features
described in most spEDS-B4GALT7 patients include
gJHM, skin hyperextensibility, radioulnar synostosis, se-
vere hypermetropia, and facial dysmorphisms (Tables 1
and 2). Skin hyperextensibility, radioulnar synostosis and
Table 2 Gene-specific minor criteria and other features of spEDS according to the 2017 EDS nosology [1, 2] and comparison to
LRS [9]
1present patient included; 2tooth discoloration, dysplastic teeth; na: not available. The gene-specific minor criteria for all types of spEDs are indicated in bold and
in light grey, in dark gray the signs observed in the present patient
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similar facial dysmorphisms have been recognized also in
patients with LRS (Tables 1 and 2). Beighton score in LRS
patients was not reported, however, all patients pre-
sented multiple dislocations highly suggestive for JHM
(Table 1, [9]). Platyspondyly, a hallmark of “spondylo”-
dysplasia, has never been recognized in spEDS-
B4GALT7 and in LRS, whereas it is frequently reported
in spEDS-B3GALT6 and spEDS-SLC39A13 (Table 2).
Given the strict clinical overlap among LRS and
spEDS-B4GALT7, in our opinion, these conditions
should not be considered as distinct entities. The pres-
ence of the same p.(Arg270Cys) mutation in both disor-
ders [6–9] further supports this hypothesis. Nevertheless,
some phenotypic variations between LRS and spEDS-
B4GALT7 exist, such as presence of bifid thumb, brachy-
mesophalangy, and glaucoma and absence of hypermetro-
pia and osteopenia in LRS [9]. These differences may stem
from the high level of homozygosity among the LRS
population and/or modification by interactions with other
variants in linkage disequilibrium to B4GALT7 [8, 9].
The recently defined gene-specific minor criteria are un-
doubtedly helpful to address molecular analysis, since
some features such as facial dysmorphism and radiological
findings have been described only among patients with a
specific subtype (Table 2). Indeed, the clinical presentation
of our patient was suggestive for B4GALT7-deficiency,
since she presented narrow mouth, wide forehead, and
single transverse palmar crease that were described only
in spEDS-B4GALT7. In addition, she showed some com-
mon gene-specific minor criteria, i.e., blue sclerae, sparse
scalp hair, flat face, osteopenia, and joint hypermobility,
but none of those that are unique of the other types
(Table 2). Even if only few spEDS-B4GALT7 patients
are reported, a wide spectrum of phenotypic severity
associated with β4Galt7-deficiency seems to exist, sug-
gesting that patients with milder phenotypes may lack
some features that have been associated with the syn-
drome. For instance, our patient did not show some as-
sumed hallmark of the disorder, i.e., radioulnar synostosis
and ID, and other frequent reported features including
proptosis, limb bowing, and hypermetropia (Table 1). It is
possible that the present patient’s milder features are due
to a less deleterious effect of her pathogenetic variant that
might retain more galactosyltransferase activity as com-
pared to the previously reported variants.
Our patient presented mild neurosensorial hearing
loss, reported up to now only in another spEDS-
B4GALT7 patient and in an individual with B3GALT6-
deficiency [Table 2], and lower limb edema of lymphatic
origin, never described before in spEDS. Presence of
hearing loss in 2/8 spEDS-B4GALT7 patients suggests
that hearing screening should be included in patients’
evaluation, at least until hearing impairment will not be
better defined by further reports. Concerning lower limb
lymphedema, though it has been reported in a 12-month-
old boy born to a consanguineous couple with a homozy-
gous B3GAT3 mutation [14], data are too scarce to specu-
late if this sign might be associated with spEDS and
overlapping disorders such as linkeropathies. Given that
we were not able to rule out some level of consanguinity
of patient’s parents, other alleles could play a role in the
pathogenesis of both hearing loss and lymphedema.
In conclusion, further reports are needed to better
characterize the B4GALT7-related phenotypes, particu-
larly, to define the incidence of the assumed specific
features, delineate genotype-phenotype correlations,
outline if LRS (and possibly also patients with B3GAT3
and XYLT1/2 mutations) should be considered as part
of spEDS phenotypic spectrum, collect natural history
data for prognostication, and to reach a critical number
of patients for therapeutic studies.
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